Shunichiro
Matsumoto

President & CEO

Shunichiro Matsumoto, Ph.D. (Shun) joined Ono Pharmaceutical Co.,Ltd. in May 2020. Prior to joining Ono, Shun has been serving as the President of Astellas Venture Management based in San Francisco Bay Area, which is the corporate venture capital arm of Astellas Pharma., Inc. At his carrier at Astellas, Shun served as board members of Mitobridge, and Potenza Therapeutics. Shun received his MBA from McGill University, and has a Ph.D. in Medicine from University of Tsukuba and MSc in Agriculture from Kyoto University. He is based at the South San Francisco office.

Kousuke
Tani

Senior
Investment Director

Kousuke Tani, Ph.D. (Kosuke) joined OVI in May 2024. He started his carrier in the pharmaceutical industry at Ono Pharmaceutical Co., Ltd. as a medicinal chemist and was involved in delivering several candidate compounds into the clinic. Before joining OVI, he led his team to plan, arrange and manage research collaborations with academia and drug discovery partnerships with biotech companies at an alliance department at Ono for 10 years. Dr. Tani has earned a Ph.D. in Chemical Engineering in 2003 from Tokyo Institute of Technology. He is based at the Cambridge office.

Haruhito
Tsutsui

Investment Director

Haruhito Tsutsui, Ph.D. (Haru) joined OVI in April 2024. Before joining OVI, he was involved in planning and managing research collaborations with academia, as well as drug discovery partnerships and licensing with biotech companies at Ono Pharmaceutical and Ono Pharma UK. His achievements include numerous collaborative projects for various indications with partners in the US, Europe, and Asia. He earned a Ph.D. in pharmaceutical sciences in 2014 from the University of Shizuoka in Shizuoka, Japan. He has expertise in central nervous system biology and biomarker discovery using omics technologies throughout his career. He is based at the South San Francisco office.

Hiroshi
Yamamoto

Investment/Operation
Senior Advisor

Hiroshi Yamamoto was assigned as the first President & CEO of OVI in its inception May 2020 and has been currently serving as the Investment/Operation Senior Advisor for OVI. He has in-depth experiences as a pharmacological researcher, business development and management side of several functional departments in the pharmaceutical industry. He has been involved in lots of depth discussions and successful deals with academia and industrial companies. Mr. Yamamoto graduated in 1994 from Kyoto Pharmaceutical University which awarded him a Master of Science in Pharmacy degree. He is based at Minase Research Institute of Ono Pharmaceutical, Osaka Japan.

Ryohei
Miyata

Director,
Scientific Relations

Ryohei Miyata, D.V.M., joined OVI in April 2025. Ryohei started his carrier as a pharmacological researcher in Ono pharmaceutical and led a project into clinical phase. Before joining OVI, he was involved in planning and managing research collaborations with academia, as well as drug discovery partnerships and licensing with biotech companies at Ono Pharmaceutical and Ono Pharma UK. Also, He was involved in managing the large comprehensive alliance including numerous drug discovery programs of oncology. He graduated in 2009 from Obihiro University of Agriculture and Veterinary Medicine. He is based at Minase Research Institute of Ono Pharmaceutical, Osaka Japan.